<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74001">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02142309</url>
  </required_header>
  <id_info>
    <org_study_id>DGM 7-2006</org_study_id>
    <nct_id>NCT02142309</nct_id>
  </id_info>
  <brief_title>Glycemic Durability After Metformin Failure</brief_title>
  <acronym>AMAZING</acronym>
  <official_title>Effect of Glimepiride, Vildagliptin, Pioglitazone and Canagliflozin on Durability of Glycemic Control After Metformin Failure in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second University of Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second University of Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is epidemic and its treatment has become more and more difficult. Consensus
      algorithms have been developed to help clinicians to select among the numerous medications
      and their combinations for achieving and maintaining a target glycated hemoglobin A1c
      (HbA1c) of &lt;7%.

      AMAZING, a pragmatic clinical trial, aims to compare commonly used oral diabetes
      medications, when combined with metformin, on glycemia-lowering effectiveness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Source data verification: paper or electronic medical records.

        -  Statistical analysis: All analyses will compare the randomly assigned treatment groups
           under the intention- to-treat principle
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is maintenance of metabolic control (glycemic durability), defined as time to primary failure with a HbA1c value &gt;7% on maximally tolerated doses of the assigned drug.</measure>
    <time_frame>Six years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous glucose monitoring for 72 consecutive hours at least once each year of follow-up</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes of low density lipoprotein cholesterol level from baseline each year of follow up</measure>
    <time_frame>6 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes of high density lipoprotein cholesterol level from baseline each year of follow up</measure>
    <time_frame>six years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes of triglyceride level from baseline each year of follow up</measure>
    <time_frame>6 years</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Glimepiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>up to 4 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>up to 30 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily</description>
    <arm_group_label>Glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Reduce to 50 mg if estimated glomerular filtration rate (eGFR) &lt;45 mL/min</description>
    <arm_group_label>Vildagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Start with 15 mg/day and advance to 30 mg/day</description>
    <arm_group_label>Pioglitazone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin</intervention_name>
    <description>Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring</description>
    <arm_group_label>Canagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly-diagnosed, type 2 diabetic patients, failing to diet

        Exclusion Criteria:

          -  Suspected type 1 diabetes or secondary diabetes resulting from specific causes

          -  Current or previous (within past 3 months) treatment with any investigational drug

          -  Any major cardiovascular event in previous year

          -  Plans for pregnancy during the course of the study for women of childbearing
             potential

          -  Serum creatinine level &gt;1.3 mg/dL in women and &gt;1.4 mg/dL in men

          -  History of cancer, other than nonmelanoma skin cancer, that required therapy in the 5
             years before randomization

          -  Treatment with oral, loal, systemic glucocorticoids 14. Treatment with atypical
             antipsychotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dario Giugliano, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second University of Naples</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dario Giugliano, MD</last_name>
    <phone>39 081 5665054</phone>
    <email>dario.giugliano@unina2.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Geriatrics and Metabolic Diseases</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Katherine Esposito</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ida Maiorino, MD</last_name>
      <email>mariaida.maiorino@unina2.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Bellastella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>April 19, 2016</lastchanged_date>
  <firstreceived_date>April 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second University of Naples</investigator_affiliation>
    <investigator_full_name>Dario Giugliano</investigator_full_name>
    <investigator_title>Full Prof of Endocrinology and Metbaolism</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
